Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.

McCabe N, Cerone MA, Ohishi T, Seimiya H, Lord CJ, Ashworth A.

Oncogene. 2009 Mar 19;28(11):1465-70. doi: 10.1038/onc.2008.483. Epub 2009 Feb 2.

PMID:
19182824
2.

Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status.

Pooley KA, McGuffog L, Barrowdale D, Frost D, Ellis SD, Fineberg E, Platte R, Izatt L, Adlard J, Bardwell J, Brewer C, Cole T, Cook J, Davidson R, Donaldson A, Dorkins H, Douglas F, Eason J, Houghton C, Kennedy MJ, McCann E, Miedzybrodzka Z, Murray A, Porteous ME, Rogers MT, Side LE, Tischkowitz M, Walker L, Hodgson S, Eccles DM, Morrison PJ, Evans DG, Eeles RA, Antoniou AC, Easton DF, Dunning AM; EMBRACE;.

Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1018-24. doi: 10.1158/1055-9965.EPI-13-0635-T. Epub 2014 Mar 18.

3.
4.

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A.

Cold Spring Harb Symp Quant Biol. 2005;70:139-48.

PMID:
16869747
5.

Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.

Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, Tsukada Y, Harrington P, Gayther SA, Ponder BA, Piver MS.

Int J Gynecol Pathol. 2004 Jan;23(1):29-34.

PMID:
14668547
6.

p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.

Sensi E, Tancredi M, Aretini P, Cipollini G, Naccarato AG, Viacava P, Bevilacqua G, Caligo MA.

Breast Cancer Res Treat. 2003 Nov;82(1):1-9.

PMID:
14672397
7.

Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic.

Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM.

Cancer Biol Ther. 2006 Sep;5(9):1098-102. Epub 2006 Sep 11.

PMID:
16931905
8.

Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.

Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN.

Cancer. 2015 Feb 1;121(3):372-8. doi: 10.1002/cncr.29058. Epub 2014 Sep 18.

9.

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN.

Cancer Genet. 2012 Jan-Feb;205(1-2):34-41. doi: 10.1016/j.cancergen.2012.01.008.

10.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB.

J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6.

11.

Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL; kConFab Investigators.

Genes Chromosomes Cancer. 2004 Mar;39(3):236-48.

PMID:
14732925
12.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.

13.

[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers].

Llort G, Peris M, Blanco I.

Med Clin (Barc). 2007 Mar 31;128(12):468-76. Review. Spanish.

PMID:
17408542
14.

Genetic Testing for BRCA Mutations Today and Tomorrow-About the ABOUT Study.

Narod S.

JAMA Oncol. 2015 Dec;1(9):1225-6. doi: 10.1001/jamaoncol.2015.3269. No abstract available.

PMID:
26426337
15.

[BRCA 1 and BRCA 2 gens in breast cancer].

Habibović S, Hrgović Z.

Lijec Vjesn. 1998 Oct-Nov;120(10-11):342-8. Review. Croatian.

PMID:
19658353
16.

BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.

Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.

PMID:
22406760
17.

CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.

Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J.

Neoplasma. 2010;57(4):325-32.

PMID:
20429623
18.

Genotype in BRCA-associated breast cancers.

Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK.

Breast J. 2013 Jan-Feb;19(1):87-91. doi: 10.1111/tbj.12056. Epub 2012 Dec 10.

19.

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W.

JAMA. 2011 Oct 12;306(14):1557-65. doi: 10.1001/jama.2011.1456. Erratum in: JAMA. 2012 Jan 25;307(4):363.

20.

Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.

Stecklein SR, Jensen RA.

Transl Res. 2012 Sep;160(3):178-97. doi: 10.1016/j.trsl.2012.01.022. Epub 2012 Feb 9. Review.

PMID:
22683426

Supplemental Content

Support Center